---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000035"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:07:46.071837+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Moderna appoints David Rubenstein to board; co-founders Langer and Berenson retire

## Summary
- David Rubenstein (Carlyle Co-Founder) joins Moderna board effective Aug 5, 2024, replacing Stephen Berenson on Audit Committee.
- Robert Langer and Stephen Berenson will retire from board on Aug 5, 2024; both will provide advisory services through Nov 1, 2026.
- Dr. Langer's and Mr. Berenson's resignations not due to any disagreement with Moderna's operations or policies.
- Board size fixed at eight directors; search ongoing for replacement with scientific/innovation experience.

## SEC filing metadata
- accession: 0001682852-24-000035
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000035/0001682852-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000035/mrna-20240719.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000035
- JSON: https://secwatch.observer/filing/0001682852-24-000035.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000035.txt

## Key facts
- Executive change
  Stephen Berenson resigned as Director at Moderna, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000035/0001682852-24-000035-index.htm
- Executive change
  Robert Langer resigned as Director at Moderna, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000035/0001682852-24-000035-index.htm
- Executive change
  David M. Rubenstein was appointed as Director at Moderna, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 19, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed David M. Rubenstein to the Board, effective August 5, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000035/0001682852-24-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.